Cat. No.: HY-14649G

Retinoic acid (GMP)

(Synonyms: Vitamin A acid (GMP); all-trans-Retinoic acid (GMP); ATRA (GMP))

Customer Review

Based on 1 Customer Validation

Retinoic acid (Vitamin A acid) (GMP) is Retinoic acid (HY-14649) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Retinoic acid is an agonist of RAR nuclear receptors.

For research use only. We do not sell to patients.

CAS No.: 302-79-4
Formula: C₂₀H₂₈O₂
Molecular Weight:300.44

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Retinoic acid (GMP) Chemical Structure

CAS No.: 302-79-4

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All RAR/RXR Isoforms :

All PPAR Isoforms :

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
3LLD122	IC₅₀	33 μM Compound: ATRA	Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50% Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%	[PMID: 10956204]
BE(2)-C	IC₅₀	6.7 μM Compound: ATRA	Antiproliferative activity against human BE2C cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay Antiproliferative activity against human BE2C cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay	[PMID: 38432288]
COLO 205	IC₅₀	37 μM Compound: ATRA	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 20405849]
COS-7	EC₅₀	0.2 nM Compound: ATRA	Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19058965]
COS-7	EC₅₀	12 nM Compound: ATRA	Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19058965]
COS-7	EC₅₀	17 nM Compound: ATRA	Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay	[PMID: 19058965]
COS-7	EC₅₀	0.6 nM Compound: ATRA	Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	[PMID: 30792038]
COS-7	EC₅₀	1.2 nM Compound: ATRA	Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	[PMID: 30792038]
COS-7	EC₅₀	1.2 nM Compound: ATRA	Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay	[PMID: 30792038]
CV-1	EC₅₀	1015 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha	[PMID: 12482435]
CV-1	EC₅₀	1211 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta	[PMID: 12482435]
CV-1	EC₅₀	19 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma	[PMID: 12482435]
CV-1	EC₅₀	436 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha	[PMID: 12482435]
CV-1	EC₅₀	78 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta	[PMID: 12482435]
CV-1	EC₅₀	961 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma	[PMID: 12482435]
CV-1	EC₅₀	0.7 nM Compound: Retinoic acid	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	[PMID: 7490725]
CV-1	EC₅₀	1 nM Compound: Retinoic acid	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	[PMID: 7490725]
CV-1	EC₅₀	7 nM Compound: Retinoic acid	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	[PMID: 7490725]
CV-1	EC₅₀	10 nM Compound: ATRA	Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	1100 nM Compound: ATRA	Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	1400 nM Compound: ATRA	Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	350 nM Compound: ATRA	Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	80 nM Compound: ATRA	Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	900 nM Compound: ATRA	Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells	[PMID: 8308867]
CV-1	EC₅₀	105 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	[PMID: 8709094]
CV-1	EC₅₀	1084 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha	[PMID: 8709094]
CV-1	EC₅₀	1225 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma	[PMID: 8709094]
CV-1	EC₅₀	1394 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta	[PMID: 8709094]
CV-1	EC₅₀	33 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	[PMID: 8709094]
CV-1	EC₅₀	563 nM Compound: ATRA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	[PMID: 8709094]
CV-1	EC₅₀	20 nM Compound: RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma	[PMID: 8978832]
CV-1	EC₅₀	459 nM Compound: RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha	[PMID: 8978832]
CV-1	EC₅₀	87 nM Compound: RA	Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta	[PMID: 8978832]
CV-1	EC₅₀	2 nM Compound: (all-E)-RA	Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta	[PMID: 9572893]
CV-1	EC₅₀	22 nM Compound: (all-E)-RA	Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha	[PMID: 9572893]
CV-1	EC₅₀	6 nM Compound: (all-E)-RA	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma	[PMID: 9572893]
CV-1	EC₅₀	>2000 nM Compound: (all-E)-RA	Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha	[PMID: 9572893]
CV-1	EC₅₀	0.7 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	1 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	1100 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	1400 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	7 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay	10.1016/0960-894X(95)00588-K
CV-1	EC₅₀	900 nM Compound: RA	Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay	10.1016/0960-894X(95)00588-K
CWR22R	GI₅₀	25.11 μM Compound: 1, ATRA	Growth inhibition of human CWR22Rv1 cells by MTT assay Growth inhibition of human CWR22Rv1 cells by MTT assay	[PMID: 25634130]
DU-145	GI₅₀	11.64 μM Compound: ATRA, Tretinoin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]
F9	IC₅₀	0.1 nM Compound: 7, trans- RA	Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days	[PMID: 17489579]
F9	ED₅₀	0.1 nM Compound: 1	Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay	[PMID: 2738885]
F9	ED₅₀	1.5 nM Compound: 1	Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay	[PMID: 2738885]
F9	ED₅₀	1.0 x 10^-10 M Compound: 1a	Ability to induce differentiation of mouse F9 embryonal carcinoma cells. Ability to induce differentiation of mouse F9 embryonal carcinoma cells.	[PMID: 2836589]
Fibroblast	IC₅₀	10 μM Compound: retinoic acid	Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs	[PMID: 18029185]
HEK-293T	IC₅₀	28.7 μM Compound: Retinoic acid	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	301.3 μM Compound: Retinoic acid	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HL-60	IC₅₀	11 μM Compound: ATRA(all-trans-retinoic acid)	Cytostatic activity against HL-60 cells Cytostatic activity against HL-60 cells	[PMID: 10585206]
HL-60	ED₅₀	1.25 μM Compound: ATRA	In vitro for the differentiation induction activity determined in the human myeloid leukemic cell line HL-60 In vitro for the differentiation induction activity determined in the human myeloid leukemic cell line HL-60	[PMID: 10956204]
HL-60	IC₅₀	11 μM Compound: ATRA	In vitro cytotoxicity against HL60 cells. In vitro cytotoxicity against HL60 cells.	[PMID: 11128648]
HL-60	IC₅₀	18 μM Compound: ATRA	In vitro inhibition of HL60 cell proliferation In vitro inhibition of HL60 cell proliferation	[PMID: 11428925]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: Retinoic acid	Effective concentration required for induction of differentiation of HL-60 cells into mature granulocytes. Effective concentration required for induction of differentiation of HL-60 cells into mature granulocytes.	[PMID: 15261256]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: 1	Concentration required for 50% inhibition of differentiation-inducing activity against human promyelocytic leukemia cell line HL-60 Concentration required for 50% inhibition of differentiation-inducing activity against human promyelocytic leukemia cell line HL-60	[PMID: 1738149]
HL-60	ED₅₀	50 nM Compound: 1	Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard. Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.	[PMID: 1992144]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: 1 (Retinoic acid)	Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes. Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes.	[PMID: 2329565]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: RA	Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction	[PMID: 2704028]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: Retinoic acid	The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte	[PMID: 2709376]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: retinoic acid	Compound was tested for differentiation-inducing activity against human promyelocytic leukemia cell line HL-60 Compound was tested for differentiation-inducing activity against human promyelocytic leukemia cell line HL-60	[PMID: 2795600]
HL-60	CC₅₀	23 nM Compound: ATRA; RA	Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay	[PMID: 33895500]
HL-60	EC₅₀	5 nM Compound: RA	Transglutaminase activity in HL-60 cdm-1 cells Transglutaminase activity in HL-60 cdm-1 cells	[PMID: 7636843]
HL-60	ED₅₀	2.4 x 10^-9 M Compound: retinoic acid	The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay	[PMID: 8182710]
HL-60	EC₅₀	5 nM Compound: RA	Induction of transglutaminase (TGase) activity in HL-60 cells Induction of transglutaminase (TGase) activity in HL-60 cells	[PMID: 8784454]
HL-60	ED₅₀	120 nM Compound: (all-E)-RA	Induction of HL-60 cells differentiation over 4 days Induction of HL-60 cells differentiation over 4 days	[PMID: 9572893]
HT-29	IC₅₀	4.3 μM Compound: ATRA	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20405849]
HT-29	CC₅₀	4.3 μM Compound: ATRA; RA	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 33895500]
LNCaP	IC₅₀	10 μM Compound: 1	Growth inhibition of human LNCaP cells after 6 days by MTT assay Growth inhibition of human LNCaP cells after 6 days by MTT assay	[PMID: 15615521]
LNCaP	IC₅₀	5 x 10^-7 M Compound: ATRA	Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 19375825]
LNCaP	GI₅₀	47.86 μM Compound: 1, ATRA	Growth inhibition of human LNCAP cells by MTT assay Growth inhibition of human LNCAP cells by MTT assay	[PMID: 25634130]
LNCaP	GI₅₀	10.33 μM Compound: ATRA, Tretinoin	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]
MCF7	IC₅₀	0.58 μM Compound: 1	Growth inhibition of human MCF7 cells after 6 days by MTT assay Growth inhibition of human MCF7 cells after 6 days by MTT assay	[PMID: 15615521]
MCF7	IC₅₀	584.5 nM Compound: 1	Antiproliferative effect against human MCF7 cells Antiproliferative effect against human MCF7 cells	[PMID: 15615521]
MCF7	GI₅₀	12.39 μM Compound: ATRA, Tretinoin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]
MCF7	IC₅₀	6.14 μM Compound: atRA	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MCF7	CC₅₀	20 nM Compound: ATRA; RA	Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay	[PMID: 33895500]
MDA-MB-231	GI₅₀	10.85 μM Compound: ATRA	Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay	[PMID: 18543902]
MDA-MB-231	GI₅₀	14.12 μM Compound: 1, ATRA	Growth inhibition of human MDA-MB-231 cells by MTT assay Growth inhibition of human MDA-MB-231 cells by MTT assay	[PMID: 25634130]
MDA-MB-231	IC₅₀	16 μM Compound: atRA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-453	GI₅₀	9.51 μM Compound: ATRA, Tretinoin	Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]
MDA-MB-468	GI₅₀	14.12 μM Compound: 1, ATRA	Growth inhibition of human MDA-MB-468 cells by MTT assay Growth inhibition of human MDA-MB-468 cells by MTT assay	[PMID: 25634130]
ME-180	CC₅₀	80 nM Compound: ATRA; RA	Antiproliferative activity against human ME-180 cells assessed as inhibition of cell growth Antiproliferative activity against human ME-180 cells assessed as inhibition of cell growth	[PMID: 33895500]
MIA PaCa-2	IC₅₀	9.5 μM Compound: ATRA	Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50% Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%	[PMID: 10956204]
MOLM-13	CC₅₀	1.24 μM Compound: ATRA; RA	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay	[PMID: 33895500]
NB-4	CC₅₀	1.5 μM Compound: ATRA; RA	Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay	[PMID: 33895500]
NB-4	ED₅₀	610 nM Compound: (all-E)-RA	Induction of NB4 cell differentiation Induction of NB4 cell differentiation	[PMID: 9572893]
Panel leukemia (Carcinoma cell lines)	ED₅₀	2.4 x 10^-9 M Compound: Retinoic acid	Effective dose for differentiation -inducing activity against human promyelocytic leukemia cells Effective dose for differentiation -inducing activity against human promyelocytic leukemia cells	[PMID: 3184125]
PC-3	IC₅₀	2 μM Compound: 1	Growth inhibition of human PC3 cells after 6 days by MTT assay Growth inhibition of human PC3 cells after 6 days by MTT assay	[PMID: 15615521]
PC-3	GI₅₀	7.6 μM Compound: ATRA	Growth inhibition of human PC3 cells after 5 days by MTT assay Growth inhibition of human PC3 cells after 5 days by MTT assay	[PMID: 18543902]
PC-3	GI₅₀	36.3 μM Compound: 1, ATRA	Growth inhibition of human PC3 cells by MTT assay Growth inhibition of human PC3 cells by MTT assay	[PMID: 25634130]
PC-3	GI₅₀	12.64 μM Compound: ATRA, Tretinoin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]
PC-3	CC₅₀	12.7 μM Compound: ATRA; RA	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 33895500]
Raji	IC₅₀	482 molar ratio Compound: retinoic acid	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells Inhibition of TPA-induced EBV-early antigen activation in human Raji cells	[PMID: 16441065]
Raji	IC₅₀	15.4 nM Compound: retinoic acid	Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs	[PMID: 17503850]
SK-BR-3	IC₅₀	1.7 nM Compound: ATRA (Retinoic acid)	Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation	[PMID: 12372520]
SK-BR-3	GI₅₀	22.9 μM Compound: 1, ATRA	Growth inhibition of human SKBR3 cells by MTT assay Growth inhibition of human SKBR3 cells by MTT assay	[PMID: 25634130]
T47D	IC₅₀	200 nM Compound: ATRA (Retinoic acid)	Inhibition of ER positive human breast cancer cell T-47D proliferation Inhibition of ER positive human breast cancer cell T-47D proliferation	[PMID: 12372520]
T47D	IC₅₀	0.006 μM Compound: 1	Growth inhibition of human T47D cells after 6 days by MTT assay Growth inhibition of human T47D cells after 6 days by MTT assay	[PMID: 15615521]
T47D	GI₅₀	0.82 μM Compound: ATRA, Tretinoin	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25701251]

In Vitro

Retinoic acid (GMP) time- and dose- dependently induces differentiation of EC cells and ES cells into specific cell types^[1].
Retinoic acid (GMP) induces partial differentiation of F9 embryonal carcinoma cells into endoderm cells^[2].
Retinoic acid (GMP) (100 nM; 2-8 d) promotes photoreceptor differentiation in early postnatal retinal cultures^[3].
Retinoic acid (GMP) (0.1 μM; 10-12 d) induces human SH-SY5Y neuroblastoma cells differentiation with long cell processes^[4].
Retinoic acid (GMP) (0-10 μM; 48 h) dose-dependently induces morphologic differentiation of LA-N-1 human neuroblastoma cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Retinoic acid (GMP) (0.3 μM; embryos are immersed in tank water containing retinoic acid) accelerates of rod differentiation is observed following 24 and 48 hours of application in zebrafish^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 302-79-4
Appearance Solid
Molecular Weight 300.44
Formula C₂₀H₂₈O₂
Color Light brown to yellow
SMILES

CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1
Synonyms

Vitamin A acid (GMP); all-trans-Retinoic acid (GMP); ATRA (GMP)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (166.42 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3285 mL

16.6423 mL

33.2845 mL

5 mM

0.6657 mL

3.3285 mL

6.6569 mL

10 mM

0.3328 mL

1.6642 mL

3.3285 mL

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Rohwedel J, et al. Induction of cellular differentiation by retinoic acid in vitro. Cells Tissues Organs. 1999;165(3-4):190-202. [Content Brief]

[2]. Sherman MI, et al. Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production. Cancer Res. [Content Brief]

[3]. Kelley MW, et al. Retinoic acid promotes differentiation of photoreceptors in vitro. Development. 1994 Aug;120(8):2091-102. [Content Brief]

[4]. Påhlman S, et al. Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ. 1984 Jun;14(2):135-44. [Content Brief]

[5]. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 1982 Apr;68(4):589-96. [Content Brief]

[6]. Hyatt GA, et al. Retinoic acid alters photoreceptor development in vivo. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13298-303. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3285 mL	16.6423 mL	33.2845 mL	83.2113 mL
	5 mM	0.6657 mL	3.3285 mL	6.6569 mL	16.6423 mL
	10 mM	0.3328 mL	1.6642 mL	3.3285 mL	8.3211 mL
	15 mM	0.2219 mL	1.1095 mL	2.2190 mL	5.5474 mL
	20 mM	0.1664 mL	0.8321 mL	1.6642 mL	4.1606 mL
	25 mM	0.1331 mL	0.6657 mL	1.3314 mL	3.3285 mL
	30 mM	0.1109 mL	0.5547 mL	1.1095 mL	2.7737 mL
	40 mM	0.0832 mL	0.4161 mL	0.8321 mL	2.0803 mL
	50 mM	0.0666 mL	0.3328 mL	0.6657 mL	1.6642 mL
	60 mM	0.0555 mL	0.2774 mL	0.5547 mL	1.3869 mL
	80 mM	0.0416 mL	0.2080 mL	0.4161 mL	1.0401 mL
	100 mM	0.0333 mL	0.1664 mL	0.3328 mL	0.8321 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Retinoic acid (GMP)

All RAR/RXR Isoforms

All PPAR Isoforms

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Retinoic acid (GMP) Related Classifications

HY-14649G Related Classifications